Bayer Signs a Three Year Multi Target AI-based Agreement with Exscientia to Treat Cardiovascular and Oncology Diseases
Shots:
- Exscientia to get up to $266.2M including upfront- research payments and clinical milestones plus royalties on sales. Bayer to get rights for the developed therapies under collaboration
- The partners will focus on early research projects combining Exscientia’s AI drug discovery platform and drug design know-how with Bayer’s data and drug discovery capabilities for the identification of therapies for cardiovascular and oncological diseases
- Exscientia’s AI-driven drug discovery platform providing novel chemical matter for targets and enables identification of therapies
Click here to read full press release/ article | Ref: Bayer | Image: Behance
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com